InVivoMAb Anti-Human Cannabinoid R1/CB1/CNR1 Antibody (6B7) (HB822030)

Name: InVivoMAb Anti-Human Cannabinoid R1/CB1/CNR1 Antibody (6B7)
Brand: abinScience
SKU: HB822030
Price: 370 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo

HB822030

Descripción

InVivoMAb Anti-Human CNR1/CB1 Nanobody (6B7) [6B7] (HB822030) is a alpaca monoclonal antibody detecting CNR1 in ELISA, Neutralization. Suitable for Human.

Reactividad de especies

Human

Aplicaciones

ELISA, Neutralization, WB

Especie huésped

Alpaca

Clonalidad

Monoclonal

Isotipo

VHH-8His-Cys-tag

ID de clon

6B7

Aplicaciones probadas

Objetivo

CNR1, CB1, CANN6, CB-R, CNR, Cannabinoid receptor 1

Nivel de endotoxinas

<0.01 EU/ug

Pureza

>95% as determined by SDS-PAGE.

Productos asociados

pH 7.4 Dilution Buffer

Purificación

Purified by Nickel column.

Número de acceso

P21554

Forma

Liquid

Buffer de almacenamiento

0.01M PBS pH 7.4

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Información de uso del producto

Aplicación	Dilución
WB	1:500-1:2000

Estabilidad y almacenamiento

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Fondo

Cannabinoid receptor 1 (CNR1/CB1) is a ~52 kDa protein. G-protein coupled receptor for endogenous cannabinoids (eCBs), including N-arachidonoylethanolamide (also called anandamide or AEA) and 2-arachidonoylglycerol (2-AG), as well as phytocannabinoids, such as delta(9)-tetrahydrocannabinol (THC). Mediates many cannabinoid-induced effects, acting, among others, on food intake, memory loss, gastrointestinal motility, catalepsy, ambulatory activity, anxiety, chronic pain. Signaling typically involves reduction in cyclic AMP. In the hypothalamus, may have a dual effect on mitochondrial respiration depending upon the agonist dose and possibly upon the cell type. Increases respiration at low doses, while decreases respiration at high doses.

1. Ryberg, E. et al. (2005) FEBS letters 579, 259-64. PMID: 15620723

2. Hua, T. et al. (2016) Cell 167, 750-762.e14. PMID: 27768894

3. Shao, Z. et al. (2016) Nature 540, 602-606. PMID: 27851727

4. Yang, X. et al. (2022) Nature chemical biology 18, 831-840. PMID: 35637350

5. Gérard, CM. et al. (1991) The Biochemical journal 279 ( Pt 1), 129-34. PMID: 1718258

6. Oddi, S. et al. (2012) British journal of pharmacology 165, 2635-51. PMID: 21895628

7. Niehaus, JL. et al. (2007) Molecular pharmacology 72, 1557-66. PMID: 17895407

8. Jourdan, T. et al. (2013) Nature medicine 19, 1132-40. PMID: 23955712

Nota

For research use only. Not suitable for clinical or therapeutic use.

Imágenes

SDS-PAGE

SDS-PAGE for InVivoMAb Anti-Human CNR1/CB1 Nanobody (6B7)
Bioactivity

Detects recombinant CNR1 (Catalog No: HB822012) in indirect ELISA.
Western blot

Western blot analysis was performed using anti-CNR1 monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human CNR1 (Catalog No: HB822012)
Immunofluorescence

Immunofluorescence staining of SHSY5Y with Alpaca monoclonal antibody (20ug/ml, overnight at 4°C), followed by Alexa Fluor-488-conjugated secondary antibody (6.5ug/ml, 50minutes at room temperature). The target protein was detected in the Cell membrane，Cytoplasm.